Quantum Biopharma (NASDAQ:QNTM – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06), Zacks reports.
Quantum Biopharma Trading Up 17.6%
Quantum Biopharma stock opened at $3.80 on Friday. The firm has a market capitalization of $24.32 million, a P/E ratio of -0.69 and a beta of 0.45. The stock has a fifty day moving average price of $3.43 and a 200 day moving average price of $4.05. Quantum Biopharma has a 52 week low of $2.07 and a 52 week high of $22.57.
Analysts Set New Price Targets
A number of research firms have recently weighed in on QNTM. Weiss Ratings lowered shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.
Institutional Trading of Quantum Biopharma
An institutional investor recently bought a new stake in Quantum Biopharma stock. Jane Street Group LLC purchased a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned 0.29% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is owned by institutional investors.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.
Featured Stories
- Five stocks we like better than Quantum Biopharma
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
